Novo Ramps Up Prandin IP Battle With Sandoz Suit

Law360, New York (October 19, 2011, 5:06 PM EDT) -- Novo Nordisk A/S filed suit Friday in New Jersey aiming to block Sandoz Inc.'s generic version of diabetes treatment Prandin, the latest broadside in an ongoing feud with generic-drug makers over a patent the U.S. Supreme Court has agreed to scrutinize later this year.

The complaint comes in response to a declaratory suit lodged by Sandoz in Michigan federal court in August over the Prandin patent.

Sandoz “knows that it stands to [gain] significant profits by supporting, promoting and encouraging the infringement” of the patent, according...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.